Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas
نویسندگان
چکیده
منابع مشابه
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, m...
متن کاملPrimary cutaneous T-cell lymphomas.
Primary cutaneous T-cell lymphomas (CTCLs) encompass a clinically and biologically heterogeneous group of non-Hodgkin lymphomas (NHLs) defined by clonal proliferation of skin-homing malignant T lymphocytes and natural killer cells. They account for up to 75% to 80% of all cutaneous lymphomas. The current WHO-EORTC classification of cutaneous lymphomas with primary cutaneous manifestations lists...
متن کاملPegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma
BACKGROUND Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Follicular cutaneous B-cell lymphoma (FCBCL) runs an indolent course. Treatment with pegylated liposomal encapsulated doxorubicin (PLE-DOXO) has yet not been r...
متن کاملPegylated liposomal doxorubicin in the treatment of mycosis fungoides.
Sir, Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. It typically evolves from the early patch and plaque stage to the cutaneous nodular or tumour stage and sometimes visceral involvement is seen in the later stage. MF is also present in an erythrodermic variant accompanied by lymphadenopathy and peripheral blood involvement, known as Sézary syndrome (1). A number of differ...
متن کاملPegylated liposomal doxorubicin in ovarian cancer
The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2007
ISSN: 0390-6078,1592-8721
DOI: 10.3324/haematol.10879